Sales or revenue reported for the first through third quarters of 2020 by biopharma companies in press announcements, annual reports, investor materials and calls. 

In 2020, the U.S. Food and Drug Administration gave the green-light to 53 new medicines (as of December 23rd) - surpassing the 48 approvals issued in 2019. Here are the top-15 drugs launched in 2020, based on sales data disclosed by the drugs’ developers through the first three quarters.

Nearly half (seven) of the products launched in 2020 were indicated for various forms of cancer — with two new treatments launched each for gastrointestinal stromal tumors (GIST), migraines and blood disorders.

One biosimilar also made the list.

Ranking #20 through #16 in Q1-Q3 2020 (not displayed) were treatments that generated between $8 to $12 million dollars.

And, as might be expected during the pandemic, two of the top 15 best-selling newly launched drugs (including the #1 ranked position) were indicated as treatments for COVID-19.